AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 May 2000 04:00 PM
RNS
Directors' Notification of Dealing in Shares
17 May 2000 04:00 PM
RNS
Directors' Notification of Dealing in Shares
17 May 2000 02:56 PM
RNS
EU Competition Authority
15 May 2000 05:34 PM
RNS
Lawsuits
08 May 2000 04:00 PM
RNS
Directors' Notification of Dealing in Shares
03 May 2000 11:00 AM
RNS
1st Quarter Results - Part 2
03 May 2000 11:00 AM
RNS
1st Quarter Results - Part 1
12 Apr 2000 09:12 AM
RNS
Notice of EGM
21 Mar 2000 05:45 PM
RNS
Proposed Merger, etc
21 Mar 2000 03:52 PM
RNS
Re Federal Patent Court Appeal
17 Mar 2000 04:00 PM
RNS
Directors' Dealings
13 Mar 2000 07:02 AM
RNS
'Nexium' Receives Fast First Approval in Sweden
09 Mar 2000 12:29 PM
RNS
Omeprazole Substance Patent Upheld in Germany
08 Mar 2000 07:02 AM
RNS
Purchase of Own Securities
07 Mar 2000 09:18 AM
RNS
Purchase of Own Securities
06 Mar 2000 07:01 AM
RNS
Purchase of Own Securities
02 Mar 2000 07:01 AM
RNS
Purchase of Own Securities
01 Mar 2000 01:39 PM
RNS
Second Interim Dividend
01 Mar 2000 12:04 PM
RNS
Directors' Dealings
01 Mar 2000 07:04 AM
RNS
Purchase of Own Securities
29 Feb 2000 07:02 AM
RNS
Purchase of Own Securities
28 Feb 2000 09:30 AM
RNS
New Drug Application for Prostate Cancer Treatment
28 Feb 2000 09:04 AM
RNS
Purchase of Own Securities
28 Feb 2000 07:01 AM
RNS
Purchase of Own Securities
24 Feb 2000 07:37 AM
RNS
Second Interim Dividend
24 Feb 2000 07:04 AM
RNS
4th Quarter & Final Results - Part 3
24 Feb 2000 07:03 AM
RNS
4th Quarter & Final Results - Part 2
24 Feb 2000 07:01 AM
RNS
4th Quarter & Final Results - Part 1
21 Feb 2000 04:31 PM
RNS
Proposed Demerger & Merger
01 Feb 2000 11:04 AM
RNS
Omeprazole SPC Case Refered to ECJ
31 Jan 2000 01:00 PM
RNS
Compulsory Acquisition Entitlement
21 Dec 1999 07:01 AM
RNS
Purchase of Own Securities
15 Dec 1999 07:01 AM
RNS
Purchase of Own Securities
14 Dec 1999 04:00 PM
RNS
Directors' Dealings
13 Dec 1999 07:01 AM
RNS
Purchase of Own Securities
10 Dec 1999 07:01 AM
RNS
Purchase of Own Securities
09 Dec 1999 07:02 AM
RNS
Purchase of Own Securities
08 Dec 1999 07:02 AM
RNS
Purchase of Own Securities
06 Dec 1999 12:06 PM
RNS
Further re New Drug Application
06 Dec 1999 09:35 AM
RNS
First Pharmaceuticals R&D Presentation - Details
03 Dec 1999 04:00 PM
RNS
Directors' Dealings
02 Dec 1999 07:02 AM
RNS
Merger of Businesses with Novartis - Part 2
02 Dec 1999 07:01 AM
RNS
Merger of Businesses with Novartis - Part 1
17 Nov 1999 08:30 AM
RNS
Interlocutory Injunction Entitlement in Israel
16 Nov 1999 04:00 PM
RNS
Directors' Dealings
12 Nov 1999 10:04 AM
RNS
German Interlocutory Injunction Denied
09 Nov 1999 04:00 PM
RNS
Directors' Dealings
28 Oct 1999 11:02 AM
RNS
3rd Quarter & 9 Months Results - Part 2
28 Oct 1999 11:00 AM
RNS
3rd Quarter & 9 Months Results - Part 1
27 Oct 1999 12:59 PM
RNS
Two Cardiovascular Medicines Divested
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100